Hyperlipidemia is a chronic metabolic disorder characterized by alterations in lipid metabolism as well as other pathways. Laportea bulbifera, an indigenous medicinal plant of Chinese herbal medicine, exhibits therapeutic effects on hyperlipidemia, but the mechanisms remain unclear. This study investigated the potential mechanisms underlying the anti‐hyperlipidemic effects of L. bulbifera using an integrated strategy based on metabolomics and network pharmacology methods that were established to investigate the potential mechanism of anti‐hyperlipidemia effect of L. bulbifera. First, the therapeutic effects of L. bulbifera on body weight reduction and biochemical indices were assessed. Next, 18 significant metabolites distinguishing the control and model groups were identified based on serum metabolomics and multivariate analyses. Then, a compound–target network was constructed by linking L. bulbifera and hyperlipidemia using network pharmacology. Three metabolic pathways involved in treating hyperlipidemia were identified. Finally, five crucial targets were selected by constructing a bionetwork starting from the compounds and ending in the metabolites. This study established an integrated strategy based on metabolomics coupled with network pharmacology and revealed the mechanism underlying the protective effects of L. bulbifera against hyperlipidemia for the first time.
Objective: Acute liver injury (ALI) has become a major reason for emergency liver transplantation mortality worldwide. Diwuyanggan (DWYG), a hospital preparation of traditional chinese medicine, does a satisfactory job of treating liver disease, but its pharmacological mechanisms should be further investigated. Thus, we aimed to unravel the mechanisms of DWYG against ALI through a comprehensive approach integrating metabolomics and network pharmacology analysis in this study. Methods: An untargeted metabolomics based on ultra-high pressure liquid chromatography together with quadrupole time of flight mass spectrometry was applied to identify differential metabolites between normal mice and thioacetamide (TAA)-induced ALI mice. By utilizing network pharmacology, potential targets against ALI caused by TAA were excavated. Subsequently, the key targets were validated by real-time polymerase chain reaction assays. Results: DWYG alleviated TAA-induced ALI. Furthermore, 28 differential metabolites were identified with an association between ALI pathological processes and DWYG effects. The pathways involved in bile acid, glycerophospholipid, fatty acid, sphingolipid, tryptophan, and tyrosine metabolism. Then, we found 127 active compounds in DWYG and 26 hub genes associated with the treatment of ALI according to network pharmacology. Besides, according to Kyoto Encyclopedia of Genes and Genome analysis, sphingolipid signaling pathway was deemed as one of the main signaling pathways involved in DWYG anti-ALI, which was in agreement with the metabolomics findings. Further, a combined analysis was performed focusing on 7 key targets, including mitogen-activated protein kinase 1, mitogen-activated protein kinase 8, caspase 3, peroxisome proliferator-activated receptor gamma, albumin, carboxylesterase 1 and glucocerebrosidase, along with their related core metabolites and pathways. Confirmatory experiment further showed that DWYG could reverse the abnormal mRNA expression of these targets in TAA mice. Conclusion: This study revealed direct evidence for the preventive effect of DWYG against ALI and the related pharmacological mechanisms.
Diet restriction (DR) ameliorates obesity by regulating mitochondrial function. Cardiolipin (CL), a mitochondrial phospholipid, is closely associated with mitochondrial function. This study aimed to evaluate the anti-obesity effects of graded levels of DR based on mitochondrial CL levels in the liver. Obese mice were treated with 0%, 20%, 40%, and 60% reductions in the normal diet compared to normal animals (0 DR, 20 DR, 40 DR, and 60 DR groups, respectively). Biochemical and histopathological analyses were performed to evaluate the ameliorative effects of DR on obese mice. The altered profile of mitochondrial CL in the liver was explored using a targeted metabolomics strategy by ultra-high-pressure liquid chromatography MS/MS coupled with quadrupole time-of-flight mass spectrometry. Finally, gene expression associated with CL biosynthesis and remodeling was quantified. Tissue histopathology and biochemical index evaluations revealed significant improvements in the liver after DR, except for the 60 DR group. The variation in mitochondrial CL distribution and DR levels showed an inverted U-shape, and the CL content in the 40 DR group was the most upregulated. This result is consistent with the results of the target metabolomic analysis, which showed that 40 DR presented more variation. Furthermore, DR led to increased gene expression associated with CL biosynthesis and remodeling. This study provides new insights into the mitochondrial mechanisms underlying DR intervention in obesity.
Cardiolipins (CLs) are involved in ATP production, mitochondria biogenesis, apoptosis and mitophagy. Their tissue distribution can provide insight into the function of mitochondria and related diseases. However, the reports on tissue distribution of CLs remain limited. In this research, CLs were identified from heart, liver, kidney, spleen, lung, skeletal muscle, and brain using ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UHPLC-QTOF-MS/MS). Then, the distribution and sex difference of CLs in seven tissues were compared by a targeted lipidomic approach. A total of 88 CLs were identified, of which 58, 51, 57, 58, 50, 61 and 52 CLs were found in heart, liver, kidney, spleen, lung, skeletal muscle, and brain, respectively. Compared with the distribution of CLs in heart, liver, kidney, and skeletal muscle, the CLs in spleen, lung, and brain showed significant differences. Moreover, the results indicated that there were sex differences of CLs in liver and kidney. A total of 16 CLs in liver tissue and 21 CLs in kidney tissue, with significant sex differences, were screened. Our findings in the targeted lipidomic analysis demonstrated that tissue distribution of CLs was essential in the dynamic states and sex differences of CLs, which might provide evidence for the mitochondrial-related mechanism under physiological and pathological conditions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.